Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01439347 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL
A Phase 3 study, sponsored by Spectrum Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT01439347 is a Phase 3 study that was terminated before completion, run by Spectrum Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT01439347, a Phase 3 study, was terminated before completion, sponsored by Spectrum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
A phase 3 study in the treatment of subjects \>or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).
Interventions
- DRUG Vincristine Sulfate Liposomes Injection (VSLI)
- DRUG Vincristine Sulfate Injection (VSI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01439347
The ClinicalTrials.gov registry entry for NCT01439347 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vincristine Sulfate Liposomes Injection (VSLI) is the first listed.
NCT01439347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01439347 about?
NCT01439347 is a clinical study titled "A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL". A phase 3 study in the treatment of subjects \>or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).
What is the current status of trial NCT01439347?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2012-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01439347?
The interventions under investigation include: Vincristine Sulfate Liposomes Injection (VSLI) (DRUG), Vincristine Sulfate Injection (VSI) (DRUG).
Who is sponsoring clinical trial NCT01439347?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.